Novel cancer-testis antigen expression on glioma cell lines derived from high-grade glioma patients

Oncology Reports

Volumn 31, Issue 4, 2014, Pages 1683-1690

  Akiyama, Yasuto ^a   Komiyama, Masaru ^a   Miyata, Haruo ^a   Yagoto, Mika ^a   Ashizawa, Tadashi ^a   Iizuka, Akira ^a   Oshita, Chie ^a   Kume, Akiko ^a   Nogami, Masahiro ^a   Ito, Ichiro ^a   Watanabe, Reiko ^a   Sugino, Takashi ^a   Mitsuya, Koichi ^a   Hayashi, Nakamasa ^a   Nakasu, Yoko ^a   Yamaguchi, Ken ^a  

^a SHIZUOKA CANCER CENTER   (Japan)

Author keywords

Cancer testis antigen; Glioma related gene expression database; High grade glioma; Immunohistochemistry; Quantitative PCR

Indexed keywords

CANCER TESTIS ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GLYCOPROTEIN GP 100; MESSENGER RNA; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE;

ADULT; ANTIGEN EXPRESSION; ARTICLE; BAGE GENE; CANCER CELL CULTURE; CASC5 GENE; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; CTAGE1 GENE; DDX43 GENE; FEMALE; GENE IDENTIFICATION; GENE OVEREXPRESSION; GLIOMA; GLIOMA CELL; GP100 GENE; HER2 GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; IL 13RA2 GENE; IMMUNOHISTOCHEMISTRY; MAGE A12 GENE; MALE; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; TDRD1 GENE; TUMOR GENE;

ANTIGENS, NEOPLASM; BRAIN NEOPLASMS; CELL LINE, TUMOR; FEMALE; GLIOMA; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM GRADING; REAL-TIME POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL;

EID: 84908131192     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2014.3049     Document Type: Article

References (34)

1. Stupp R, Mason WP, van den Bent MJ, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996, 2005.
2. Mirimanoff RO, Gorlia T, Mason W, et al: Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. J Clin Oncol 24: 2563-2569, 2006.
3. Ikushima H, Todo T, Ino Y, Takahashi M, Miyazawa K and Miyazono K: Autocrine TGF-β signaling maintains tumorigenicity of glioma-initiating cells through Sry-related HMG-box factors. Cell Stem Cell 5: 504-514, 2009.
4. McFarland BC, Ma JY, Langford CP, Gillespie GY, Yu H, Zheng Y, Nozell SE, Huszar D and Benveniste EN: Therapeutic potential of AZD1480 for the treatment of human glioblastoma. Mol Cancer Ther 10: 2384-2393, 2011.
5. Sai K, Wang S, Balasubramaniyan V, et al: Induction of cell-cycle arrest and apoptosis in glioblastoma stem-like cells by WP1193, a novel small molecule inhibitor of the JAK2/STAT3 pathway. J Neurooncol 107: 487-501, 2012.
6. Ashizawa T, Miyata H, Ishii H, et al: Antitumor activity of a novel small molecules STAT3 inhibitor against a human lymphoma cell line with high STAT3 activation. Int J Oncol 38: 1245-1252, 2011.
7. Zhou Y, Liu F, Xu Q and Wang X: Analysis of the expression profile of Dickkopf-1 gene in human glioma and the association with tumor malignancy. J Exp Clin Cancer Res 29: 138, 2010.
8. Reardon DA, Fink KL, Mikkelsen T, et al: Randomized phase II study of cilemgitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol 26: 5610-5617, 2008.
9. Jo J, Schiff D and Purow B: Angiogenic inhibition in high-grade gliomas: past, present and future. Expert Rev Neurother 12: 733-747, 2012.
10. Chang CN, Huang YC, Yang DM, Kikuta K, Wei KJ, Kubota T and Yang WK: A phase I/II clinical trial investigating the adverse and therapeutic effects of a postoperative autologous dendritic cell tumor vaccine in patients with malignant glioma. J Clin Neurosci 18: 1048-1054, 2011.
11. Luptrawan A, Liu G and Yu JS: Dendritic cell immunotherapy for malignant gliomas. Rev Recent Clin Trials 3: 10-21, 2008.
12. Ardon H, Van Gool SW, Verschuere T, et al: Intergation of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: results of the HGG-2006 phase I/II trial. Cancer Immunol Immunother 61: 2033-2044, 2012.
13. Ardon H, Van Gool S, Lopes IS, et al: Integration of autologous dendritic cell-based immunotherapy in the primary treatment for patients with newly diagnosed glioblastoma multiforme: a pilot study. J Neurooncol 99: 261-272, 2010.
14. Oji Y, Suzuki T, Nakano Y, et al: Overexpression of the Wilms' tumor gene WT1 in primary astrocytic tumors. Cancer Sci 95: 822-827, 2004.
15. Bodey B, Siegel SE and Kaiser HE: MAGE-1, a cancer/testis-antigen, expression in childhood astrocytomas as an indicator of tumor progression. In vivo 16: 583-588, 2002.
16. Liu G, Ying H, Zeng G, Wheeler CJ, Black KL and Yu JS: HER-2, gp100, and MAGE-1 are expressed in human glioblastoma and recognized by cytotoxic T cells. Cancer Res 64: 4980-4986, 2004.
17. Debinski W and Gibo DM: Molecular expression analysis of restrictive receptor for interleukin 13, a brain tumor-associated cancer/testis antigen. Mol Med 6: 440-449, 2000.
18. Schmits R, Cochlovius B, Treitz G, et al: Analysis of the antibody repertoire of astrocytoma patients against antigens expressed by gliomas. Int J Cancer 98: 73-77, 2002.
19. Yawata T, Nakai E, Park KC, et al: Enhanced expression of cancer testis antigen genes in glioma stem cells. Mol Carcinog 49: 532-544, 2010.
20. Oba-Shinjo SM, Caballero OL, Jungbluth AA, Rosemberg S, Old LJ, Simpson AJ and Marie SK: Cancer-testis (CT) antigen expression in medulloblastoma. Cancer Immun 8: 7, 2008.
21. Syed ON, Mandigo CE, Killory BD, Canoll P and Bruce JN: Cancer-testis and melanocyte-differentiation antigen expression in malignant glioma and meningioma. J Clin Neurosci 19: 1016-1021, 2012.
22. Sahin U, Koslowski M, Tureci O, et al: Expression of cancer testis genes in human brain tumors. Clin Cancer Res 6: 3916-3922, 2000.
23. Renkvist N, Castelli C, Robbins PF and Parmiani G: A listing of human tumor antigens recognized by T cells. Cancer Immunol Immunother 50: 3-15, 2001.
24. Nestle FO, Alijagic S, Gilliet M, et al: Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 4: 328-332, 1998.
25. Akiyama Y, Tanosaki R, Inoue N, et al: Clinical response in Japanese metastatic melanoma patients treated with peptide cocktail-pulsed dendritic cells. J Transl Med 3: 4, 2005.
26. Tyagi P and Mirakhur B: MAGRIT: the largest-ever phase III lung cancer trial aims to establish a novel tumor-specific approach to therapy. Clin Lung Cancer 10: 371-374, 2009.
27. Aoki M, Ueda S, Nishikawa H, et al: Antibody responses against NY-ESO-1 and HER2 antigens in patients vaccinated with combinations of cholesteryl pullulan (CHP)-NY-ESO-1 and CHP-HER2 with OK-432. Vaccine 27: 6854-6861, 2009.
28. Okada H, Kalinski P, Ueda R, et al: Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with α-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. J Clin Oncol 29: 330-336, 2011.
29. Chi DD, Merchant RE, Rand R, et al: Molecular detection of tumor-associated antigens shared by human cutaneous melanomas and gliomas. Am J Pathol 150: 2143-2152, 1997.
30. Hegi ME, Diserens AC, Gorlia T, et al: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352: 997-1003, 2005.
31. Hegi ME, Liu L, Herman LG, et al: Correlation of O6- methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol 26: 4189-4199, 2008.
32. Quinn JA, Jiang SX, Reardon DA, et al: Phase II trial of temozolomide plus O6-benzylguanine in adults with recurrent, temozolomide- resistant maliganant glioma. J Clin Oncol 27: 1262-1267, 2009.
33. Natsume A, Wakabayashi T, Tsujimura K, et al: The DNA demethylating agent 5-aza-2′-deoxycytidine activates NY-ESO-1 antigenicity in orthotopic human glioma. Int J Cancer 122: 2542-2553, 2008.
34. Low J, Dowless M, Shiyanova T, et al: Knockdown of cancer testis antigens modulates neural stem cell marker expression in glioblastoma tumor stem cells. J Biomol Screen 15: 830-839, 2010.